

## SUPPLEMENTARY TABLES

**Supplementary Table 1. Basal mRNA expression [reads per kilobase per million mapped (RPKM) values] of ABT-263 target BCL2 family genes in mouse and human small intestine.**

BCL family gene (symbol)	Mouse [1]	Human [2]
B-cell leukemia/lymphoma 2 ( <i>Bcl2</i> )	0.381	2.13
Bcl2 like 1 ( <i>Bcl2l1</i> or <i>Bcl-xL</i> )	<b>4.549</b>	<b>16.92</b>
Bcl2 like 2 ( <i>Bcl2l2</i> or <i>Bcl-w</i> )	2.64	13.5

**Supplementary Table 2. List of pro-inflammatory and GI cancer-associated serum factors upregulated after <sup>28</sup>Si exposure and mitigated using ABT-263.**

Protein name (symbol)	Role in inflammation	Role in GI cancer development
Tumor Necrosis Factor Receptor Superfamily, Member 1B (TNFRSF1B)	Yes [3]	Yes [4]
Chemokine (C-C Motif) Ligand 20 (CCL20)	Yes [5]	Yes [5]
Chemokine (C-X-C Motif) ligand 4 (CXCL4)	Yes [6]	Yes [7, 8]
P-Selectin (SELP)	Yes [9]	Yes [10]
Chemokine (C-C Motif) Ligand 27 (CCL27)	Yes [11]	Yes [11]
Chemokine (C-X-C Motif) Ligand 16 (CXCL16)	Yes [12]	Yes [13, 14]

**Supplementary Table 3. List of significantly altered serum cytokines in response to ABT-263.**

Protein	Fold change (± SEM)	Regulation
AXL Receptor Tyrosine Kinase (Axl)	-1.27± 0.07*	Down
Tumor Necrosis Factor (ligand) Super Family Member 6 (TNFSF6)	-1.42±0.04*	Down
Fractalkine (CX2CL1)	-1.47±0.32*	Down
Granulocyte-Colony Stimulating Factor (G-CSF)	-1.40±0.04*	Down
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)	-1.33 ±0.02*	Down
Interferon Gamma (IFN-gamma)	-1.21 ± 0.03*	Down
C-C Motif Chemokine Ligand 5 (CCL5)	1.24 ± 0.02*	Up
Tissue Inhibitor of Metalloproteinase 1 (TIMP1)	1.22 ± 0.02*	Up
Tumor Necrosis Factor Receptor Superfamily Member 1B (TNFRSF1B)	1.00 ± 0.008	Unchanged
C-C Motif Chemokine Ligand 20 (CCL20)	1.15 ± 0.03	Unchanged
Chemokine (C-X-C Motif) Ligand 4 (CXCL4)	1.09 ± 0.001	Unchanged
P-Selectin	-1.03 ± 0.07	Unchanged
C-C Motif Chemokine Ligand 27 (CCL27)	1.15 ± 0.11	Unchanged
C-X-C Motif Chemokine Ligand 16 (CXCL16)	1.20 ± 0.11*	Up

\*Significantly altered in ABT-263 group relative to vehicle group [cut-off of 1.2-fold at  $p < 0.05$ ].

## REFERENCES

1. Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shores N, Adrian J, Kawli T, Davis CA, Dobin A, Kaul R, Halow J, Van Nostrand EL, Freese P, et al, and ENCODE Project Consortium. Expanded encyclopaedias of DNA elements in the human and mouse genomes. *Nature*. 2020; 583:699–710.  
<https://doi.org/10.1038/s41586-020-2493-4>  
PMID:[32728249](https://pubmed.ncbi.nlm.nih.gov/32728249/)
2. Fagerberg L, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpour S, Danielsson A, Edlund K, Asplund A, Sjöstedt E, Lundberg E, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol Cell Proteomics*. 2014; 13:397–406.  
<https://doi.org/10.1074/mcp.M113.035600>  
PMID:[24309898](https://pubmed.ncbi.nlm.nih.gov/24309898/)
3. Pan S, Liu R, Wu X, Ma K, Luo W, Nie K, Zhang C, Meng X, Tong T, Chen X, Wang X, Deng M. LncRNA NEAT1 mediates intestinal inflammation by regulating TNFRSF1B. *Ann Transl Med*. 2021; 9:773.  
<https://doi.org/10.21037/atm-21-34> PMID:[34268386](https://pubmed.ncbi.nlm.nih.gov/34268386/)
4. Zhao T, Li H, Liu Z. Tumor necrosis factor receptor 2 promotes growth of colorectal cancer via the PI3K/AKT signaling pathway. *Oncol Lett*. 2017; 13:342–6.  
<https://doi.org/10.3892/ol.2016.5403> PMID:[28123565](https://pubmed.ncbi.nlm.nih.gov/28123565/)
5. Olsen RS, Nijm J, Andersson RE, Dimberg J, Wågsäter D. Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer. *World J Gastroenterol*. 2017; 23:6212–9.  
<https://doi.org/10.3748/wjg.v23.i34.6212>  
PMID:[28974887](https://pubmed.ncbi.nlm.nih.gov/28974887/)
6. Silva-Cardoso SC, Tao W, Angiolilli C, Lopes AP, Bekker CP, Devaprasad A, Giovannone B, van Laar J, Cossu M, Marut W, Hack E, de Boer RJ, Boes M, et al. CXCL4 Links Inflammation and Fibrosis by Reprogramming Monocyte-Derived Dendritic Cells *in vitro*. *Front Immunol*. 2020; 11:2149.  
<https://doi.org/10.3389/fimmu.2020.02149>  
PMID:[33042127](https://pubmed.ncbi.nlm.nih.gov/33042127/)
7. Zhang Y, Gao J, Wang X, Deng S, Ye H, Guan W, Wu M, Zhu S, Yu Y, Han W. CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity. *Cancer Biol Ther*. 2015; 16:1775–83.  
<https://doi.org/10.1080/15384047.2015.1095404>  
PMID:[26479470](https://pubmed.ncbi.nlm.nih.gov/26479470/)
8. Ruytinx P, Proost P, Struyf S. CXCL4 and CXCL4L1 in cancer. *Cytokine*. 2018; 109:65–71.  
<https://doi.org/10.1016/j.cyto.2018.02.022>  
PMID:[29903575](https://pubmed.ncbi.nlm.nih.gov/29903575/)
9. Schürmann GM, Bishop AE, Facer P, Vecchio M, Lee JC, Rampton DS, Polak JM. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. *Gut*. 1995; 36:411–8.  
<https://doi.org/10.1136/gut.36.3.411> PMID:[7535284](https://pubmed.ncbi.nlm.nih.gov/7535284/)
10. Qi C, Wei B, Zhou W, Yang Y, Li B, Guo S, Li J, Ye J, Li J, Zhang Q, Lan T, He X, Cao L, et al. P-selectin-mediated platelet adhesion promotes tumor growth. *Oncotarget*. 2015; 6:6584–96.  
<https://doi.org/10.18632/oncotarget.3164>  
PMID:[25762641](https://pubmed.ncbi.nlm.nih.gov/25762641/)
11. Song M, Sasazuki S, Camargo MC, Shimazu T, Charvat H, Yamaji T, Sawada N, Kemp TJ, Pfeiffer RM, Hildesheim A, Pinto LA, Rabkin CS, Tsugane S. Circulating inflammatory markers and colorectal cancer risk: A prospective case-cohort study in Japan. *Int J Cancer*. 2018; 143:2767–76.  
<https://doi.org/10.1002/ijc.31821> PMID:[30132835](https://pubmed.ncbi.nlm.nih.gov/30132835/)
12. Lehrke M, Konrad A, Schachinger V, Tillack C, Seibold F, Stark R, Parhofer IG, Broedl UC. CXCL16 is a surrogate marker of inflammatory bowel disease. *Scand J Gastroenterol*. 2008; 43:283–8.  
<https://doi.org/10.1080/00365520701679249>  
PMID:[18938659](https://pubmed.ncbi.nlm.nih.gov/18938659/)
13. AbdelMageed M, Ali H, Olsson L, Lindmark G, Hammarström ML, Hammarström S, Sitohy B. The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome. *Int J Mol Sci*. 2019; 20:5793.  
<https://doi.org/10.3390/ijms20225793>  
PMID:[31752131](https://pubmed.ncbi.nlm.nih.gov/31752131/)
14. Korbecki J, Bajdak-Rusinek K, Kupnicka P, Kapczuk P, Simińska D, Chlubek D, Baranowska-Bosiacka I. The Role of CXCL16 in the Pathogenesis of Cancer and Other Diseases. *Int J Mol Sci*. 2021; 22:3490.  
<https://doi.org/10.3390/ijms22073490>  
PMID:[33800554](https://pubmed.ncbi.nlm.nih.gov/33800554/)